<DOC>
	<DOCNO>NCT02109978</DOCNO>
	<brief_summary>This study examine extreme responder second- third-line Type 2 Diabetes ( T2D ) therapy use retrospective approach patient slow fast diabetes progression .</brief_summary>
	<brief_title>RetroMASTER - Retrospective Cohort MRC ABPI STratification Extreme Response Mechanism Diabetes</brief_title>
	<detailed_description>PILOT Phase ( March 2013 - Dec 2014 ) Patients recruit initially 2 centre , plus Exeter pre-PILOT centre . Patients particularly good poor response second- third-line Type 2 diabetes treatment patient progress insulin either particularly quickly particularly slowly recruit primary , secondary , community setting . Fasting blood urine sample collect , along standard biomeasures information collect medical history prescribe history . All study documentation sample material send site coordinate centre . Sites expect process freeze sample send Central Laboratory manage Chief Inspector 's site analyse genetic factor , glycaemic marker marker related drug response . POST-PILOT Phase ( Jan 2015- Oct 2017 ) : Subject feasibility , interim analysis continuation fund Medical Research Council ( MRC ) , project continue another three year .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Generic Demographics : Age 1890 inclusive Ethnicity : Reflective local demographic Medical History : Clinical diagnosis Type 2 diabetes Mental Capacity : Capacity Consent Responders Cohort On Sulphonylurea , DPP4 inhibitor , GLP1R agonist , SGLT2 inhibitor Glitazone &gt; 4 month . Pretreatment HbA1c≥ 58mmol/mol ( 7.5 % ) . Progressors Cohort Type 2 diabetes ( insulin treatment within 6 month diagnosis ) Either : requirement insulin treatment ≤10 year diagnosis ( defined insulin treatment HbA1c ≥ 69mmol/mol ( 8/5 % ) treat two noninsulin diabetes therapy ) : requirement insulin treatment &gt; 10 year diagnosis ( defined insulin treatment AND HbA1c &lt; 69mmol/mol ( 8.5 % ) . Age le 18 year old great 90 year old Incapacity consent Type 1 diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Diabetes therapy response</keyword>
	<keyword>Diabetes progression</keyword>
</DOC>